Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue (2012 - 2020)

Agios Pharmaceuticals has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $491000.0 in Q2 2020.

• For the quarter ending Q2 2020, Non-Current Deffered Revenue fell 99.05% year-over-year to $491000.0; the trailing twelve-month figure through Jun 2020 stood at $491000.0 (down 99.05% YoY), and the FY2019 full-year result was $50.6 million, down 15.43% from the prior year.
• Non-Current Deffered Revenue for Q2 2020 stood at $491000.0, down from $571000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $173.9 million in Q3 2016, with the low at $491000.0 in Q2 2020.
• Historically, Non-Current Deffered Revenue has averaged $57.7 million across 5 years, with a median of $50.2 million in 2019.
• Annual changes were most pronounced in 2016 — Non-Current Deffered Revenue soared 12486.47% — and 2020, when it tumbled 99.05%.
• Agios Pharmaceuticals' Non-Current Deffered Revenue stood at $17.8 million in 2016, then soared by 607.8% to $125.8 million in 2017, then sank by 52.46% to $59.8 million in 2018, then slipped by 15.43% to $50.6 million in 2019, then sank by 99.03% to $491000.0 in 2020.
• The last three Non-Current Deffered Revenue figures came in at $491000.0 (Q2 2020), $571000.0 (Q1 2020), and $50.6 million (Q4 2019), per Business Quant data.